Abstract

The vascular endothelium is present within metabolic organs and actively regulates energy metabolism. Here we show osteocalcin, recognized as a bone-secreted metabolic hormone, is expressed in mouse primary endothelial cells isolated from heart, lung and liver. In human osteocalcin promoter-driven green fluorescent protein transgenic mice, green fluorescent protein signals are enriched in endothelial cells lining aorta, small vessels and capillaries and abundant in aorta, skeletal muscle and eye of adult mice. The depletion of lipoprotein receptor-related protein 1 induces osteocalcin through a Forkhead box O -dependent pathway in endothelial cells. Whereas depletion of osteocalcin abolishes the glucose-lowering effect of low-density lipoprotein receptor-related protein 1 depletion, osteocalcin treatment normalizes hyperglycemia in multiple mouse models. Mechanistically, osteocalcin receptor-G protein-coupled receptor family C group 6 member A and insulin-like-growth-factor-1 receptor are in the same complex with osteocalcin and required for osteocalcin-promoted insulin signaling pathway. Therefore, our results reveal an endocrine/paracrine role of endothelial cells in regulating insulin sensitivity, which may have therapeutic implications in treating diabetes and insulin resistance through manipulating vascular endothelium.

The vascular endothelium contributes to metabolic regulation, however, the underlying mechanisms are not fully understood. Here the authors show that endothelial low-density lipoprotein receptor-related protein 1 regulates glucose homeostasis via osteocalcin expression.

Details

Title
Endothelium-specific depletion of LRP1 improves glucose homeostasis through inducing osteocalcin
Author
Mao Hua 1 ; Li, Luge 1 ; Fan Qiying 1 ; Angelini Aude 1   VIAFID ORCID Logo  ; Saha, Pradip K 2 ; Coarfa Cristian 3   VIAFID ORCID Logo  ; Kimal, Rajapakshe 3 ; Perera Dimuthu 3 ; Cheng, Jizhong 4 ; Wu Huaizhu 1 ; Ballantyne, Christie M 1   VIAFID ORCID Logo  ; Sun, Zheng 5   VIAFID ORCID Logo  ; Xie, Liang 1 ; Pi Xinchun 1   VIAFID ORCID Logo 

 Section of Athero & Lipo, Baylor College of Medicine, Department of Medicine, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); Baylor College of Medicine, Cardiovascular Research Institute, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X) 
 Baylor College of Medicine, Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Diabetes Research Center, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X) 
 Baylor College of Medicine, Departments of Molecular and Cellular Biology, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); Baylor College of Medicine, Dan L. Duncan Cancer Center, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X) 
 Baylor College of Medicine, Department of Medicine, Section of Nephrology, Selzman Institute for Kidney Health, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X) 
 Baylor College of Medicine, Department of Medicine, Division of Diabetes, Endocrinology & Metabolism, Diabetes Research Center, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X); Baylor College of Medicine, Departments of Molecular and Cellular Biology, Houston, USA (GRID:grid.39382.33) (ISNI:0000 0001 2160 926X) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2569483615
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.